Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel declines after ...

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...

Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction ...

Life Science Washington, the state's life sciences industry association, today announced the expansion of its board of directors with the addition of nine new members, representing distinguished ...

Real-time index price for KBW Regional Banking Index (KRX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

According to the consensus that consist of 29 analysts, the target price for Vertex is ranged from $325.00 to $591.00 with the average of $495.25. GuruFocus estimates the value for Vertex is $434.37, ...